

conforms to the standards prescribed by § 443.20(a)(1).

(2) *Labeling.* It shall be labeled in accordance with the requirements of § 432.5 of this chapter.

(3) *Requests for certification; samples.* In addition to complying with the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(A) The loracarbef used in making the batch for potency, moisture, pH, specific rotation, crystallinity, and identity.

(B) The batch for content, moisture, dissolution, and identity.

(ii) Samples, if required by the Director, Center for Drug Evaluation and Research:

(A) The loracarbef used in making the batch: 10 packages, each containing approximately 500 milligrams.

(B) The batch: A minimum of 100 capsules.

(b) *Tests and methods of assay—(1) Loracarbef content.* Proceed as directed in § 443.20(b)(1), preparing the sample solution and calculating the loracarbef content as follows:

(i) *Preparation of sample solution.* Place one intact capsule in a 200-milliliter volumetric flask containing 150 milliliters of distilled water. Shake the mixture vigorously to aid disruption of the capsule. Sonicate the mixture briefly (5 minutes). Dilute the contents to volume with distilled water. Mix well and immediately transfer a suitable aliquot to a volumetric flask of appropriate size to obtain a solution containing 0.2 milligram per milliliter (estimated) of loracarbef when diluted to volume with mobile phase (described in § 443.20(b)(1)(i)). Filter this solution through a 0.45-micron membrane filter before injecting it into the chromatograph.

(ii) *Calculations.* Calculate the loracarbef content as follows:

$$\text{Milligrams of loracarbef per capsule} = \frac{A_U \times P_s \times d}{A_s \times 1,000}$$

where:

$A_U$ =Area of the loracarbef peak in the chromatogram of the sample (at a retention time equal to that observed for the standard);

$A_s$ =Area of the loracarbef peak in the chromatogram of the loracarbef working

standard;

$P_s$ =Loracarbef activity in the loracarbef working standard solution in micrograms per milliliter; and

$d$  = Dilution factor of the sample.

(2) *Moisture.* Proceed as directed in § 436.201 of this chapter.

(3) *Dissolution test.* Proceed as directed in § 436.215 of this chapter. The quantity  $Q$ , the amount of loracarbef activity dissolved, is 75 percent within 30 minutes.

(4) *Identity.* The retention time of the loracarbef response in the high-performance liquid chromatographic procedure described in paragraph (b)(1) of this section as applied to the sample solution compares qualitatively to that of the loracarbef reference standard.

**§ 443.120b Loracarbef for oral suspension.**

(a) *Requirements for certification—(1) Standards of identity, strength, quality, and purity.* Loracarbef for oral suspension is loracarbef with one or more suitable and harmless preservatives, sweeteners, suspending agents, colorings, antifoaming agents, and flavorings. When constituted as directed in the labeling, each milliliter contains the equivalent of either 20 or 40 milligrams loracarbef activity. Its loracarbef content is satisfactory if it is not less than 90 percent and not more than 115 percent of the number of milligrams of loracarbef that it is represented to contain. Its moisture content is not more than 2.0 percent. When constituted as described in the labeling, the pH of the suspension is not less than 3.5 and not more than 6.0. It passes the identity test. The loracarbef used conforms to the standards prescribed by § 443.20(a)(1).

(2) *Labeling.* It shall be labeled in accordance with the requirements of § 432.5 of this chapter.

(3) *Requests for certification; samples.* In addition to complying with the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(A) The loracarbef used in making the batch for potency, moisture, pH, specific rotation, crystallinity, and identity.

(B) The batch for content, moisture, pH, and identity.

(ii) Samples, if required by the Director, Center for Drug Evaluation and Research:

(A) The loracarbef used in making the batch: 10 packages, each containing approximately 500 milligrams.

(B) The batch: A minimum of 10 immediate containers.

(b) *Tests and methods of assay*—(1) *Loracarbef content*. Proceed as directed in §443.20(b)(1), preparing the sample solution and calculating the loracarbef content as follows:

(i) *Preparation of sample solution*. Constitute as directed in the labeling. Transfer a 5.0-milliliter portion of the suspension into an appropriately sized volumetric flask and quantitatively dilute stepwise with mobile phase (described in §443.20(b)(1)(i)) to obtain a concentration of 0.2 milligram of loracarbef activity per milliliter (estimated).

(ii) *Calculations*. Calculate the loracarbef content as follows:

$$\frac{\text{Milligrams of loracarbef}}{\text{per 5 milliliters of sample}} = \frac{A_U \times P_s \times d}{A_s \times 1,000}$$

where:

$A_U$ =Area of the loracarbef peak in the chromatogram of the sample (at a retention time equal to that observed for the standard);

$A_s$ =Area of the loracarbef peak in the chromatogram of the loracarbef working standard;

$P_s$ =Loracarbef activity in the loracarbef working standard solution in micrograms per milliliter; and

$d$  = Dilution factor of the sample.

(2) *Moisture*. Proceed as directed in §436.201 of this chapter.

(3) *pH*. Proceed as directed in §436.202 of this chapter, using the drug constituted as directed in the labeling.

(4) *Identity*. The retention time of the loracarbef response in the high-performance liquid chromatographic procedure described in paragraph (b)(1) of this section as applied to the sample solution compares qualitatively to that of the loracarbef reference standard.

## PART 444—OLIGOSACCHARIDE ANTIBIOTIC DRUGS

### Subpart A—Bulk Drugs

Sec.

444.6 Amikacin.

444.7 Amikacin sulfate.

444.10a Dihydrostreptomycin sulfate, crystalline dihydrostreptomycin sulfate, dihydrostreptomycin hydrochloride.

444.20 Gentamicin sulfate.

444.20a Sterile gentamicin sulfate.

444.30 Kanamycin sulfate.

444.30a Sterile kanamycin sulfate.

444.42 Neomycin sulfate.

444.42a Sterile neomycin sulfate.

444.46 Netilmicin sulfate.

444.50 Paromomycin sulfate.

444.62 Sisomicin sulfate.

444.70a Sterile streptomycin sulfate.

444.80 Tobramycin.

444.81a Sterile tobramycin sulfate.

### Subpart B—Oral Dosage Forms

444.130 Kanamycin sulfate capsules.

444.142 Neomycin sulfate oral dosage forms.

444.142a Neomycin sulfate tablets.

444.142b Neomycin sulfate oral solution.

444.150 Paromomycin sulfate oral dosage forms.

444.150a Paromomycin sulfate capsules.

444.150b Paromomycin sulfate sirup.

### Subpart C—Injectable Dosage Forms

444.206 Amikacin sulfate injection.

444.220 Gentamicin sulfate injection.

444.230 Kanamycin sulfate injection.

444.246 Netilmicin sulfate injection.

444.262 Sisomicin sulfate injection.

444.270 Streptomycin sulfate injectable dosage forms.

444.270a Sterile streptomycin sulfate.

444.270b Streptomycin sulfate injection.

444.280 Tobramycin sulfate injection.

444.281 Sterile tobramycin sulfate.

### Subpart D—Ophthalmic Dosage Forms

444.320 Gentamicin sulfate ophthalmic dosage forms.

444.320a Gentamicin sulfate ophthalmic solution.

444.320b Gentamicin sulfate ophthalmic ointment.

444.320c Gentamicin sulfate-prednisolone acetate ophthalmic suspension.

444.320d Gentamicin sulfate-prednisolone acetate ophthalmic ointment.

444.342 Neomycin sulfate ophthalmic dosage forms.

444.342a Neomycin sulfate-\_\_\_\_\_ ophthalmic suspension; neomycin sulfate-\_\_\_\_\_ ophthalmic solution (the blanks being filled in with the established name(s) of the other active ingredient(s) present in accordance with paragraph (a)(1) of this section).

444.342b Neomycin sulfate-polymyxin B sulfate-gramicidin ophthalmic solution.

444.342c Neomycin sulfate-gramicidin